维生素D及白细胞介素-6水平在结直肠癌患者预后评估中的价值

Value of vitamin D and IL-6 levels in serum on the prognosis of colorectal carcinoma

目的探讨维生素D及白细胞介素-6水平在结直肠癌患者预后评估中的价值。方法选取树兰(杭州)医院2016-2017年经病理学证实的结直肠癌患者45例和同期健康体检者53例,检测患者外周血中维生素D、白细胞介素-6水平。根据检测结果,将结直肠癌患者分为维生素D高表达组和低表达组以及白细胞介素-6高表达组和低表达组,分别比较各组患者临床病理参数,并对患者进行预后评估。结果结直肠癌患者外周血中维生素D含量为(6.43±3.71)ng/mL,低于健康对照组的(10.21±3.54)ng/mL,(P<0.01);白细胞介素-6水平为17.5(8.97~42.92)ng/mL,高于健康对照组的9.15(3.51~13.79)ng/mL,(P<0.01),且二者在结直肠癌组织中的水平可能具有相关性(χ2=7.4,P<0.01)。维生素D及白细胞介素-6水平与结直肠癌患者是否发生淋巴结核转移、TNM分期和肿瘤浸润深度密切相关。预后分析发现,血清维生素D浓度与患者预后呈正相关,血清白细胞介素-6水平与患者预后呈负相关。结论维生素D及白细胞介素-6水平与结直肠癌患者预后有关,可作为判断结直肠癌患者预后的新型、有效的生物学指标。

Objective To discuss the value of vitamin D（VD）and IL-6 levels in serum on the prognosis of colorectal carcinoma.Methods 45 patients with pathologically confirmed colorectal cancer and 53 healthy volunteers were enrolled in this study.The levels of serum VD and IL-6 were detected and compared.The patients were further divided into high VD expression group,low VD expression group,high IL-6 expression group or low IL-6 expression group.The correlation between serum VD and IL-6 levels and clinical pathological parameters were analyzed.The clinical pathological features were compared between groups,and the prognoses of patients were analyzed.Results The VD level in colorectal cancer group was lower than that in the healthy volunteer group.[（6.43±3.71）ng/mL vs.（10.21±3.54）ng/mL,P〈0.01];The IL-6 level in colorectal cancer group was 17.5（8.97-42.92）ng/mL,higher than the 9.15（3.51-13.79）ng/mL in the healthy volunteers group（P〈0.01）.There might be a correlation between the VD level and IL-6 level in colorectal cancer tissue.The levels of serum VD and IL-6 were closely correlated with lymph node metastasis,the TNM staging,and the depth of tumor invasion.Serum VD level was positively while serum IL-6 level was negatively correlated with prognosis.Conclusion The serum VD and IL-6 levels of patients with colorectal cancer are associated with prognosis,which can be used as novel and effective biological indicators for evaluating the prognosis of colorectal cancer.